ATEL Private Debt Partners III
ATEL Private Debt Partners III is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at ATEL Private Debt Partners III.
ATEL Private Debt Partners III is a company.
Key people at ATEL Private Debt Partners III.
Key people at ATEL Private Debt Partners III.
ATEL Private Debt Partners III, LLC is a private debt fund managed by ATEL Capital Group, a San Francisco-based firm specializing in venture debt and equipment leasing.[3][2][6] It provides non-dilutive financing to high-growth companies across sectors like technology, healthcare, life sciences, energy, and sustainable solutions, enabling startups to extend runway, fund equipment, or reach milestones without equity dilution.[1][2] ATEL's investment philosophy emphasizes flexible venture debt structures—free from bank-like covenants—allowing founders to retain control while scaling, with a track record of backing ventures for over 25 years.[1][5]
The fund supports the startup ecosystem by offering fast capital access (streamlined from inquiry to funding) to early- and late-stage companies, often alongside equity rounds, and has financed firms like biotech Vial ($10M) and Menlo Micro for manufacturing expansion.[1][2] Sector-agnostic but capital-intensive focused, it complements ATEL's broader portfolio in equipment leasing to corporations like Berkshire Hathaway subsidiaries.[2][6]
ATEL Capital Group, the parent entity, was formed in 1977, initially focusing on equipment lease financing for investment-grade companies.[6] By 1999, its division ATEL Growth Capital (AGC) launched to provide debt financing to high-growth ventures, evolving from equipment leasing into venture debt amid rising startup needs.[5] Key figures include Chairman and CEO Dean Cash, COO Paritosh K. Choksi, and Senior VP Bill Bullock, based at 505 Montgomery Street in San Francisco.[3][5]
ATEL Private Debt Partners III, LLC emerged as a recent vehicle in this lineage, with SEC filings confirming its structure at the same San Francisco address; it follows predecessors like ATEL Growth Capital Fund III (AGCF III), which raised up to $25M in 2006.[3][4] This evolution reflects ATEL's shift toward private debt funds to capitalize on venture debt demand, including proactive use in Europe and U.S. biotechs.[2]
ATEL Private Debt Partners III rides the venture debt surge amid high interest rates and cautious equity markets, where startups seek non-dilutive capital to bridge to profitability or acquisitions.[1][2] Timing aligns with capital-intensive trends like biotech trials (Vial), manufacturing ramps (Menlo Micro), and sustainable tech, where equity alone falls short for equipment/infrastructure.[2] Market forces favoring it include European adoption of strategic debt—extending runways without mega-rounds—and U.S. shifts post-2022 downturn, reducing dilution risks.[2]
It influences the ecosystem by enabling scale for underserved high-growth firms, fostering innovation in cleantech and life sciences without heavy VC control, and complementing ATEL's leasing to blue-chips for diversified returns.[1][6]
ATEL Private Debt Partners III is poised to expand amid sustained venture debt demand, potentially closing related funds by 2025 and targeting more biotechs/electromechanical innovators.[5][2] Trends like AI-driven manufacturing and climate tech will shape it, amplifying non-dilutive financing as equity costs rise. Its influence may grow via larger facilities and global outreach, solidifying ATEL's role as a quiet growth catalyst for ambitious ventures—much like its 25-year backing of sector disruptors.[1]